Verition Fund Management
KRYS icon

Verition Fund Management’s Krystal Biotech KRYS Stock Holding History

Verition Fund Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,969
Closed -$4.18M – 2975
2025
Q4 		$4.18M Sell
16,969
-14,364
-46% -$3.02M 0.02% 1016
2025
Q3 		$5.53M Buy
31,333
+4,819
+18% +$721K 0.02% 1051
2025
Q2 		$3.64M Buy
26,514
+7,889
+42% +$1.16M 0.02% 1438
2025
Q1 		$3.36M Sell
18,625
-6,277
-25% -$1.06M 0.02% 1183
2024
Q4 		$3.9M Buy
24,902
+8,902
+56% +$1.58M 0.02% 1069
2024
Q3 		$2.91M Sell
16,000
-1,989
-11% -$384K 0.01% 1190
2024
Q2 		$3.3M Sell
17,989
-43,811
-71% -$7.36M 0.02% 980
2024
Q1 		$11M Sell
61,800
-34,158
-36% -$4.74M 0.08% 303
2023
Q4 		$11.9M Sell
95,958
-31,112
-24% -$3.45M 0.09% 193
2023
Q3 		$14.7M Buy
127,070
+35,338
+39% +$4.31M 0.17% 141
2023
Q2 		$10.8M Sell
91,732
-1,912
-2% -$195K 0.14% 181
2023
Q1 		$7.5M Buy
93,644
+13,083
+16% +$1.03M 0.1% 256
2022
Q4 		$6.38M Buy
80,561
+12,909
+19% +$958K 0.1% 250
2022
Q3 		$4.71M Buy
67,652
+12,908
+24% +$933K 0.05% 433
2022
Q2 		$3.59M Buy
54,744
+23,578
+76% +$1.47M 0.07% 384
2022
Q1 		$2.07M Sell
31,166
-44,948
-59% -$2.81M 0.02% 942
2021
Q4 		$5.32M Buy
76,114
+10,069
+15% +$586K 0.04% 336
2021
Q3 		$3.45M Buy
66,045
+47,464
+255% +$2.81M 0.03% 383
2021
Q2 		$1.26M Sell
18,581
-51,266
-73% -$3.58M 0.01% 702
2021
Q1 		$5.38M Sell
69,847
-7,697
-10% -$560K 0.06% 184
2020
Q4 		$4.65M Buy
77,544
+21,515
+38% +$1.07M 0.04% 214
2020
Q3 		$2.41M Sell
56,029
-10,457
-16% -$454K 0.05% 217
2020
Q2 		$2.75M Sell
66,486
-19,504
-23% -$938K 0.09% 171
2020
Q1 		$3.72M Buy
85,990
+61,798
+255% +$3.23M 0.15% 104
2019
Q4 		$1.34M Sell
24,192
-45,002
-65% -$2.21M 0.02% 364
2019
Q3 		$2.4M Buy
69,194
+6,544
+10% +$293K 0.07% 205
2019
Q2 		$2.52M Buy
+62,650
New +$2.05M 0.07% 195

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verition Fund Management's KRYS Position: Q1 2026 in Review

Verition Fund Management sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 16,969 shares — an estimated $4.18M sold.

Verition Fund Management first reported a position in KRYS in Q2 2019 and held it in 27 quarters. The position peaked at $14.7M in Q3 2023. 368 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Verition Fund Management reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 16,969 Krystal Biotech shares in Q1 2026, an estimated $4.18M.
  • Verition Fund Management first reported a position in Krystal Biotech in Q2 2019 and held it in 27 quarters.
  • Verition Fund Management's Krystal Biotech position peaked at $14.7M in Q3 2023.
  • 368 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.